UK to Accept More China Clinical Trial Data as Power Shifts

The UK drug regulator will accept more data from clinical trials in China to accelerate drug approvals, a shift in stance that runs counter to the US approach.

While there is no plan for a blanket acceptance of Chinese data, the UK’s Medicines and Healthcare products Regulatory Agency wants to leverage the depth of research coming out of China at an ever-increasing rate. The regulator plans to set out a strategy later this year.